Heterogeneity of the aggregation response of human platelets to arginine vasopressin

No abstract is available for this paper.

• Publication year

  1995

• Venue

  American journal of hematology/oncology

• Publication date

  1995-05-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1002/ajh.2830490110PMID 7741139
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• INTERNATIONAL JOURNAL OF MULTIDISCIPLINARY: APPLIED BUSINESS AND EDUCATION RESEARCH

  2023cited by this paper
• Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor.

  1994cited by this paper
• Modulation of Vasopressin Actions on Human Platelets by Plasma Adenosine and Theophylline: Gender Differences

  1993cited by this paper
• The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C.

  1991cited by this paper
• Reproducibility and temporal stability of ADP‐induced platelet aggregation: Comparison of the anticoagulants sodium citrate and D‐phenylalanyl‐L‐prolyl‐L‐arginyl chloromethyl ketone

  1991cited by this paper
• Desmopressin-induced improvement in bleeding times in chronic renal failure patients correlates with platelet serotonin uptake and ATP release.

  1990cited by this paper
• Effect of 1-desamino-8-D-arginine vasopressin (DDAVP) on human platelets.

  1990cited by this paper
• Vasopressin agonists and antagonists.

  1990cited by this paper
• Platelet vasopressin receptor in patients with chronic renal failure.

  1989cited by this paper
• Ionized calcium as an intracellular messenger in blood platelets.

  1989cited by this paper
• Platelet cytosolic free calcium in essential hypertension: responses to vasopressin.

  1989cited by this paper
• Biochemical mechanisms of platelet activation.

  1989cited by this paper
• Homologous regulation of human platelet vasopressin receptors does not occur in vivo.

  1989cited by this paper
• HORMONAL CONTROL OF GENE EXPRESSION

  1988cited by this paper
• CHARACTERIZATION OF HUMAN PLATELET VASOPRESSIN RECEPTOR AND THE RELATION BETWEEN VASOPRESSIN‐INDUCED PLATELET AGGREGATION AND VASOPRESSIN BINDING TO PLATELETS

  1988cited by this paper
• Platelet Aggregation and Vasopressin Receptors in Patients with Diabetes Mellitus

  1988cited by this paper
• Mechanisms of action of vasopressin and vasopressin antagonists.

  1988cited by this paper
• Hemoglobin E: An emerging hemoglobinopathy in the United States

  1987cited by this paper
• V1a-vasopressin specific receptors on human platelets: potentiation by ADP and epinephrine and evidence for homologous down-regulation.

  1987cited by this paper
• Human platelet fraction arginine-vasopressin. Potential physiological role.

  1987cited by this paper
• Selective Agonists and Antagonists of Vasopressin

  1987cited by this paper
• Relations among sodium pump inhibition, Na-Ca and Na-H exchange activities, and Ca-H interaction in cultured chick heart cells.

  1987cited by this paper
• The Human Platelet Vasopressin Receptor and Its Intracellular Messengers: Key Role of Divalent Cations

  1987cited by this paper
• HUMAN PLATELET ARGININE VASOPRESSIN

  1986cited by this paper
• Desensitization and antagonism of vasopressin-induced phosphoinositide metabolism and elevation of cytosolic free calcium concentration in human platelets.

  1986cited by this paper
• Activation of V1-receptors by vasopressin stimulates inositol phospholipid hydrolysis and arachidonate metabolism in human platelets.

  1986cited by this paper
• Nature and properties of human platelet vasopressin receptors.

  1986cited by this paper
• Characterization of human platelet vasopressin receptors.

  1985cited by this paper
• Pharmacological characterization of vasopressin aggregation response of human platelets.

  1985cited by this paper
• Subcellular localization of vasopressin-like material in platelets.

  1985cited by this paper
• Inhibition of the pentose phosphate shunt by lead: a potential mechanism for hemolysis in lead poisoning.

  1984cited by this paper
• The role of cytoplasmic free calcium in the responses of quin2-loaded human platelets to vasopressin.

  1984cited by this paper
• Effect of heparin on platelet aggregation

  1984cited by this paper
• Vasopressin inhibits the adenylate cyclase activity of human platelet particulate fraction through V1‐receptors

  1983cited by this paper
• Some properties of the human platelet vasopressin receptor.

  1983cited by this paper
• Plasma and Platelet Vasopressin in Essential Hypertension and Congestive Heart Failure

  1983cited by this paper
• The use of prostacyclin in the separation from plasma and washing of human platelets.

  1982cited by this paper
• Human platelet vasopressin receptors.

  1982cited by this paper
• Distribution, blood transport, and degradation of antidiuretic hormone in man.

  1976cited by this paper
• Mechanism of Plasminogen Activator and Factor VIII Increase after Vasoactive Drugs

  1975cited by this paper
• Aggregation of human blood platelets by vasopressin.

  1972cited by this paper

• Adverse Clinical Effects Associated With Non-catecholamine Pharmacologic Agents for Treatment of Vasoplegic Syndrome in Adult Cardiac Surgery.

  2023cites this paper
• Short article: Impact of genetic variation in the vasopressin 1a receptor on the development of organ failure in patients admitted for acute decompensation of liver cirrhosis

  2017cites this paper
• Vasopressin and terlipressin in neonates and children with refractory septic shock.

  2013cites this paper
• Age-related losses of retinal ganglion cells and axons.

  2008cites this paper
• Gene expression profiling for the identification of G-protein coupled receptors in human platelets.

  2008cites this paper
• Vasopressin vs. terlipressinin the treatmentof cardiovascular failure in sepsis

  2008cites this paper
• Arginine vasopressin in vasodilatory shock: effects on metabolism and beyond

  2008cites this paper
• Comparative investigation of the effect of vasopressin and of its structural analogue DGAVP on aggregation of blood platelets

  2008cites this paper
• Modeling the effects of aging on retinal ganglion cell density and nerve fiber layer thickness

  2008cites this paper
• Study of V1a vasopressin receptor gene single nucleotide polymorphisms in platelet vasopressin responsiveness

  2006cites this paper
• Science Review: Vasopressin and the cardiovascular system part 1 – receptor physiology

  2003cites this paper
• [Comparison of local differential luminance sensitivity (dls) between Oculus Twinfield Perimeter and Humphrey Field Analyzer 630 (HFA I) in normal volunteers of varying ages].

  2001cites this paper
• Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud's phenomenon.

  2000cites this paper
• Study of V(1)-vascular vasopressin receptor gene microsatellite polymorphisms in human essential hypertension.

  2000cites this paper
• Variable Interindividual Responses to Antiplatelet Therapies – Do They Exist, Can We Measure Them, and Are They Clinically Relevant?

  2000cites this paper
• Study of V1-vascular Vasopressin Receptor Gene Microsatellite Polymorphisms in Human Essential Hypertension☆

  2000cites this paper
• In vitro and in vivo effects of desmopressin on platelet function.

  1999cites this paper
• Lack of vasopressin-induced platelet aggregation in healthy subjects

  1999cites this paper
• Vasopressin and platelets: a concise review.

  1997cites this paper
• Partial Inhibition of Na/K-ATPase by Ouabain Induces the Ca-dependent Expressions of Early-response Genes in Cardiac Myocytes (*)

  1996cites this paper
• Physiologic concentrations of arginine vasopressin activate human platelets in vitro

  1996cites this paper
• Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine.

  1994cites this paper